Is Required for Panitumumab Efficacy in Patients With Metastatic Colorectal Cancer, Journal of Clinical Oncology, vol.26, issue.10, pp.1626-1660, 2008. ,
DOI : 10.1200/JCO.2007.14.7116
Mutations As an Independent Prognostic Factor in Patients With Advanced Colorectal Cancer Treated With Cetuximab, Journal of Clinical Oncology, vol.26, issue.3, pp.374-383, 2008. ,
DOI : 10.1200/JCO.2007.12.5906
URL : https://hal.archives-ouvertes.fr/hal-00363737
The KRAS oncogene: Past, present, and future, Biochimica et Biophysica Acta (BBA) - Reviews on Cancer, vol.1756, issue.2, pp.81-83, 2005. ,
DOI : 10.1016/j.bbcan.2005.10.001
Effect of Fixatives and Tissue Processing on the Content and Integrity of Nucleic Acids, The American Journal of Pathology, vol.161, issue.6, pp.1961-71, 2002. ,
DOI : 10.1016/S0002-9440(10)64472-0
The Isolation of Nucleic Acids from Fixed, Paraffin-Embedded Tissues???Which Methods Are Useful When?, PLoS ONE, vol.35, issue.6, p.537, 2007. ,
DOI : 10.1371/journal.pone.0000537.s002
PCR-introduced loop structure as primer in DNA sequencing, Biotechniques, vol.25, pp.876-884, 1998. ,
ras oncogenes in human cancer: a review, Cancer Res, vol.49, pp.4682-4691, 1989. ,
Distinct patterns of KRAS mutations in colorectal carcinomas according to germline mismatch repair defects and hMLH1 methylation status, Human Molecular Genetics, vol.13, issue.19, pp.2303-2314, 2004. ,
DOI : 10.1093/hmg/ddh238
Pyrosequencing: History, biochemistry and future, Clinica Chimica Acta, vol.363, issue.1-2, pp.83-94, 2006. ,
DOI : 10.1016/j.cccn.2005.04.038
Erlotinib as first-time treatment for untreated advance stage NSCLC with good prognosis, J Clin Oncol, vol.24, p.408, 2006. ,
Epidemiology of Lung Cancer: Looking to the Future, Journal of Clinical Oncology, vol.23, issue.14, pp.3175-3185, 2005. ,
DOI : 10.1200/JCO.2005.10.462
Is Required for Panitumumab Efficacy in Patients With Metastatic Colorectal Cancer, Journal of Clinical Oncology, vol.26, issue.10, pp.1626-1634, 2008. ,
DOI : 10.1200/JCO.2007.14.7116
The epidermal growth factor receptor: from mutant oncogene in nonhuman cancers to therapeutic target in human neoplasia, J Clin Oncol, vol.19, pp.32-40, 2001. ,
Detection of EGFR Gene Mutation in Lung Cancer by Mutant-Enriched Polymerase Chain Reaction Assay, Clinical Cancer Research, vol.12, issue.1, pp.43-48, 2006. ,
DOI : 10.1158/1078-0432.CCR-05-0934
The 2004 World Health Organization classification of lung tumors, Seminars in Roentgenology, vol.40, issue.2, 2005. ,
DOI : 10.1053/j.ro.2005.01.001
Epidermal Growth Factor Receptor Mutations and Gene Amplification in Non???Small-Cell Lung Cancer: Molecular Analysis of the IDEAL/INTACT Gefitinib Trials, Journal of Clinical Oncology, vol.23, issue.31, pp.8081-8092, 2005. ,
DOI : 10.1200/JCO.2005.02.7078
Colorectal cancer prevalence in France, European Journal of Cancer Prevention, vol.9, issue.5, pp.303-307, 2000. ,
DOI : 10.1097/00008469-200010000-00003
Epidemiologic of primary bronchial carcinoma management in the general French hospital centers], Rev Mal Respir, vol.19, pp.727-734, 2002. ,
Epidemiology of environmental and occupational cancer, Oncogene, vol.23, issue.38, pp.6392-6403, 2004. ,
DOI : 10.1038/sj.onc.1207715
Enhanced apoptosis with combination C225/radiation treatment serves as the impetus for clinical investigation in head and neck cancers, J Clin Oncol, vol.18, pp.47-53, 2000. ,
Radiotherapy plus Cetuximab for Squamous-Cell Carcinoma of the Head and Neck, New England Journal of Medicine, vol.354, issue.6, pp.567-578, 2006. ,
DOI : 10.1056/NEJMoa053422
ras oncogenes in human cancer: a review, Cancer Res, vol.49, pp.4682-4689, 1989. ,
Energy Intake, Body Mass Index, Physical Activity, and the Colorectal Adenoma-Carcinoma Sequence, Nutrition and Cancer, vol.39, issue.1, pp.50-57, 2001. ,
DOI : 10.1207/S15327914nc391_7
Tobacco, alcohol, and colorectal tumors: a multistep process, Am J Epidemiol, vol.141, pp.1038-1046, 1995. ,
The new World Health Organization classification of lung tumours, European Respiratory Journal, vol.18, issue.6, pp.1059-1068, 2001. ,
DOI : 10.1183/09031936.01.00275301
K-ras oncogene mutations in sporadic colorectal cancer in The Netherlands Cohort Study, Carcinogenesis, vol.24, issue.4, pp.703-710, 2003. ,
DOI : 10.1093/carcin/bgg009
Randomized Phase II Study of Gemcitabine Plus Cisplatin or Carboplatin, With or Without Cetuximab, As First-Line Therapy for Patients With Advanced or Metastatic Non???Small-Cell Lung Cancer, Journal of Clinical Oncology, vol.25, issue.36, pp.5777-5784, 2007. ,
DOI : 10.1200/JCO.2007.13.0856
Improving the efficacy of antibody-based cancer therapies, Nature Reviews Cancer, vol.1, issue.2, pp.118-129, 2001. ,
DOI : 10.1038/35101072
Detection of Epidermal Growth Factor Receptor Variations by Partially Denaturing HPLC, Clinical Chemistry, vol.53, issue.1, pp.62-70, 2007. ,
DOI : 10.1373/clinchem.2006.074831
Antitumor activity of sequential treatment with topotecan and anti-epidermal growth factor receptor monoclonal antibody C225, Clin Cancer Res, vol.5, pp.909-916, 1999. ,
A novel approach in the treatment of cancer: targeting the epidermal growth factor receptor, Clin Cancer Res, vol.7, pp.2958-2970, 2001. ,
The deaf and the dumb: the biology of ErbB-2 and ErbB-3, Experimental Cell Research, vol.284, issue.1, pp.54-65, 2003. ,
DOI : 10.1016/S0014-4827(02)00101-5
K-ras point mutation detection in lung cancer: comparison of two approaches to somatic mutation detection using ARMS allele-specific amplification, Clin Chem, vol.46, pp.1929-1938, 2000. ,
website de l'US National Institute of Health relative aux essais cliniques, dernière consultation le 20.10, 2009. ,
Evaluation of denaturing high-performance liquid chromatography as a rapid detection method for identification of epidermal growth factor receptor mutations in nonsmall-cell lung cancer, Cancer, vol.12, issue.12, pp.2858-2865, 2006. ,
DOI : 10.1002/cncr.22331
ABX-EGF in combination with paclitaxel and carboplatine for advanced non-small cell lung cancer (NSCLC), J Clin Oncol, vol.22, p.14, 2004. ,
Cetuximab Monotherapy and Cetuximab plus Irinotecan in Irinotecan-Refractory Metastatic Colorectal Cancer, New England Journal of Medicine, vol.351, issue.4, pp.337-345, 2004. ,
DOI : 10.1056/NEJMoa033025
Cancers bronchopulmonaires primitives non à petites cellules et tumeurs à malignité réduite. EMC-pneumologie 6-002-H-20, p.16, 1998. ,
KRAS wild-type state predicts survival and is associated to early radiological response in metastatic colorectal cancer treated with cetuximab, Annals of Oncology, vol.19, issue.3, pp.508-515, 2008. ,
DOI : 10.1093/annonc/mdm496
Mutations and addiction to EGFR: the Achilles ???heal??? of lung cancers?, Trends in Molecular Medicine, vol.10, issue.10, pp.481-486, 2004. ,
DOI : 10.1016/j.molmed.2004.08.008
Gefitinib in Combination With Gemcitabine and Cisplatin in Advanced Non???Small-Cell Lung Cancer: A Phase III Trial???INTACT 1, Journal of Clinical Oncology, vol.22, issue.5, pp.777-784, 2004. ,
DOI : 10.1200/JCO.2004.08.001
Erlotinib for Frontline Treatment of Advanced Non-Small Cell Lung Cancer: a Phase II Study, Clinical Cancer Research, vol.12, issue.20, pp.6049-6055, 2006. ,
DOI : 10.1158/1078-0432.CCR-06-0260
The Isolation of Nucleic Acids from Fixed, Paraffin-Embedded Tissues???Which Methods Are Useful When?, PLoS ONE, vol.35, issue.6, p.537, 2007. ,
DOI : 10.1371/journal.pone.0000537.s002
Epidermal growth factor receptor immunohistochemical reactivity in patients with American Joint Committee on Cancer Stage IV colon adenocarcinoma, Cancer, vol.43, issue.5, pp.1331-1346, 2001. ,
DOI : 10.1002/1097-0142(20010901)92:5<1331::AID-CNCR1455>3.0.CO;2-M
A polymorphism of EGFR extracellular domain is associated with progression free-survival in metastatic colorectal cancer patients receiving cetuximab-based treatment, BMC Cancer, vol.91, issue.21, p.169, 2008. ,
DOI : 10.1073/pnas.91.21.10217
Timeline: The discovery of receptor tyrosine kinases: targets for cancer therapy, Nature Reviews Cancer, vol.4, issue.5, pp.361-370, 2004. ,
DOI : 10.1038/nrc1360
Optimization of Patient Selection for Gefitinib in Non-Small Cell Lung Cancer by Combined Analysis of Epidermal Growth Factor Receptor Mutation, K-ras Mutation, and Akt Phosphorylation, Clinical Cancer Research, vol.12, issue.8, pp.2538-2544, 2006. ,
DOI : 10.1158/1078-0432.CCR-05-2845
Phase II Trial of Cetuximab in Patients With Previously Treated Non???Small-Cell Lung Cancer, Journal of Clinical Oncology, vol.24, issue.33, pp.5253-5258, 2006. ,
DOI : 10.1200/JCO.2006.08.2263
Gefitinib in Combination With Paclitaxel and Carboplatin in Advanced Non???Small-Cell Lung Cancer: A Phase III Trial???INTACT 2, Journal of Clinical Oncology, vol.22, issue.5, 2004. ,
DOI : 10.1200/JCO.2004.07.215
Automated real-time PCR to determine K-ras codon 12 mutations in non-small cell lung cancer: Comparison with immunohistochemistry and clinico-pathological features, International Journal of Oncology, vol.23, pp.1121-1126, 2003. ,
DOI : 10.3892/ijo.23.4.1121
The frequency of cancer in France in year 2002, and trends since 1968], Bull Cancer, vol.93, pp.7-11, 2006. ,
Epidermal Growth Factor Receptor in Non???Small-Cell Lung Carcinomas: Correlation Between Gene Copy Number and Protein Expression and Impact on Prognosis, Journal of Clinical Oncology, vol.21, issue.20, pp.3798-3807, 2003. ,
DOI : 10.1200/JCO.2003.11.069
The ErbB receptors and their role in cancer progression, Experimental Cell Research, vol.284, issue.1, pp.99-110, 2003. ,
DOI : 10.1016/S0014-4827(02)00099-X
: Directing Key Signaling Networks Throughout Life, Annual Review of Pharmacology and Toxicology, vol.44, issue.1, pp.195-217, 2004. ,
DOI : 10.1146/annurev.pharmtox.44.101802.121440
A susceptibility locus for lung cancer maps to nicotinic acetylcholine receptor subunit genes on 15q25, Nature, vol.38, issue.7187, pp.633-637, 2008. ,
DOI : 10.1038/nature06885
URL : https://hal.archives-ouvertes.fr/cea-00944415
ERBB receptors and cancer: the complexity of targeted inhibitors, Nature Reviews Cancer, vol.7, issue.5, pp.341-354, 2005. ,
DOI : 10.1021/jm00130a020
EGFR kinase domain mutations ??? functional impact and relevance for lung cancer therapy, Oncogene, vol.37, issue.39, pp.5693-5701, 2007. ,
DOI : 10.1038/sj.onc.1210383
Quantitative detection of mutant alleles of the K-ras gene with minor groove binder-conjugated fluorogenic DNA probes, International Journal of Oncology, vol.24, pp.687-696, 2004. ,
DOI : 10.3892/ijo.24.3.687
A Rapid and Sensitive Enzymatic Method for Epidermal Growth Factor Receptor Mutation Screening, Clinical Cancer Research, vol.12, issue.3, pp.751-758, 2006. ,
DOI : 10.1158/1078-0432.CCR-05-2047
Cancer Statistics, 2008, Cancer statistics, pp.71-96, 2008. ,
DOI : 10.3322/CA.2007.0010
Inhibition of epidermal growth factor receptor kinase induces protease-dependent apoptosis in human colon cancer cells?????????, Gastroenterology, vol.114, issue.5, pp.930-939, 1998. ,
DOI : 10.1016/S0016-5085(98)70312-9
Detection of Epidermal Growth Factor Receptor Mutations in Serum as a Predictor of the Response to Gefitinib in Patients with Non-Small-Cell Lung Cancer, Clinical Cancer Research, vol.12, issue.13, pp.3915-3921, 2006. ,
DOI : 10.1158/1078-0432.CCR-05-2324
Epigen, the Last Ligand of ErbB Receptors, Reveals Intricate Relationships between Affinity and Mitogenicity, Journal of Biological Chemistry, vol.280, issue.9, pp.8503-8512, 2005. ,
DOI : 10.1074/jbc.M413919200
Analysis of Epidermal Growth Factor Receptor Gene Mutation in Patients with Non-Small Cell Lung Cancer and Acquired Resistance to Gefitinib, Clinical Cancer Research, vol.12, issue.19, pp.5764-5769, 2006. ,
DOI : 10.1158/1078-0432.CCR-06-0714
The KRAS oncogene: Past, present, and future, Biochimica et Biophysica Acta (BBA) - Reviews on Cancer, vol.1756, issue.2, pp.81-82, 2005. ,
DOI : 10.1016/j.bbcan.2005.10.001
Tyrosine Kinases as Targets for Cancer Therapy, New England Journal of Medicine, vol.353, issue.2, pp.172-187, 2005. ,
DOI : 10.1056/NEJMra044389
Efficacy of Gefitinib, an Inhibitor of the Epidermal Growth Factor Receptor Tyrosine Kinase, in Symptomatic Patients With Non???Small Cell Lung Cancer, JAMA, vol.290, issue.16, pp.2149-2158, 2003. ,
DOI : 10.1001/jama.290.16.2149
High resolution melting analysis for the rapid and sensitive detection of mutations in clinical samples: KRAS codon 12 and 13 mutations in non-small cell lung cancer, BMC Cancer, vol.52, issue.12, p.295, 2006. ,
DOI : 10.1373/clinchem.2006.068205
TNM Staging of Lung Cancer, Chest, vol.115, issue.1, pp.233-235, 1999. ,
DOI : 10.1378/chest.115.1.233
DNA sequencing technologies: A revolution in motion, pp.260-279, 2008. ,
Epidemiology of tobacco smoking], Rev Mal Respir, vol.22, pp.8-27, 2005. ,
Absence ofEGFR mutation in the kinase domain in common human cancers besides non-small cell lung cancer, International Journal of Cancer, vol.86, issue.3, pp.510-511, 2005. ,
DOI : 10.1002/ijc.20591
KRAS Mutation Status Is Predictive of Response to Cetuximab Therapy in Colorectal Cancer, Cancer Research, vol.66, issue.8, pp.3992-3995, 2006. ,
DOI : 10.1158/0008-5472.CAN-06-0191
Mutations As an Independent Prognostic Factor in Patients With Advanced Colorectal Cancer Treated With Cetuximab, Journal of Clinical Oncology, vol.26, issue.3, pp.374-379, 2008. ,
DOI : 10.1200/JCO.2007.12.5906
URL : https://hal.archives-ouvertes.fr/hal-00363737
The Evolving Role of Cetuximab in Non-Small Cell Lung Cancer, Clinical Cancer Research, vol.12, issue.14, pp.4432-4435, 2006. ,
DOI : 10.1158/1078-0432.CCR-06-0097
Randomized phase II trial of single agent erlotinib vs. standard chemotherapy in patients with advanced non-small cell lung cancer (NSCLC) and performance status (PS) of 2 Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib, J Clin Oncol N Engl J Med, vol.24, issue.350, pp.2129-2139, 2004. ,
A randomized multicenter phase III study of cetuximab (Erbitux ® ) in combination with Taxane/Carboplatin vs Taxane/Carboplatin alone first-line treatment for patients with advanced/metastatic Non-small cell lung cancer (NSCLC), th World Conference on Lung Cancer, pp.340-341, 2002. ,
A phase II trial of ZD1839 (Iressa?) 750 mg per day, an oral epidermal growth factor receptor-tyrosine kinase inhibitor, in patients with metastatic colorectal cancer, Investigational New Drugs, vol.17, issue.(11 suppl 12), pp.165-170, 2005. ,
DOI : 10.1007/s10637-005-5862-9
Epithelial immaturity and multiorgan failure in mice lacking epidermal
growth factor receptor, Nature, vol.376, issue.6538, pp.337-341, 1995. ,
DOI : 10.1038/376337a0
The Epstein-Barr virus latent membrane protein 1 induces expression of the epidermal growth factor receptor, J Virol, vol.69, pp.4390-4398, 1995. ,
An update on epidermal growth factor receptor inhibitors, Current Oncology Reports, vol.20, issue.Suppl 2, pp.47-55, 2002. ,
DOI : 10.1007/s11912-002-0047-6
amplification in advanced non-small cell lung cancer, Cancer Science, vol.24, issue.12, pp.2455-2460, 2008. ,
DOI : 10.1111/j.1349-7006.2008.00962.x
Gene copy number for epidermal growth factor receptor (EGFR) and clinical response to antiEGFR treatment in colorectal cancer: a cohort study, The Lancet Oncology, vol.6, issue.5, pp.279-286, 2005. ,
DOI : 10.1016/S1470-2045(05)70102-9
Frequent expression of a mutant epidermal growth factor receptor in multiple human tumors, Cancer Res, vol.55, pp.5536-5539, 1995. ,
Constitutive Activation of Phosphatidylinositol 3-Kinase by a Naturally Occurring Mutant Epidermal Growth Factor Receptor, Journal of Biological Chemistry, vol.273, issue.1, pp.200-206, 1998. ,
DOI : 10.1074/jbc.273.1.200
Somatic Mutations of Epidermal Growth Factor Receptor in Colorectal Carcinoma, Clinical Cancer Research, vol.11, issue.4, pp.1368-1371, 2005. ,
DOI : 10.1158/1078-0432.CCR-04-1894
EGFR and cancer prognosis, European Journal of Cancer, vol.37, issue.4, pp.9-15, 2001. ,
DOI : 10.1016/S0959-8049(01)00231-3
Tyrosine Kinase Inhibitors Targeted to the Epidermal Growth Factor Receptor Subfamily, Drugs, vol.11, issue.4, pp.753-767, 2000. ,
DOI : 10.2165/00003495-200059040-00003
Sensitive Sequencing Method for KRAS Mutation Detection by Pyrosequencing, The Journal of Molecular Diagnostics, vol.7, issue.3, pp.413-421, 2005. ,
DOI : 10.1016/S1525-1578(10)60571-5
Distinct patterns of KRAS mutations in colorectal carcinomas according to germline mismatch repair defects and hMLH1 methylation status, Human Molecular Genetics, vol.13, issue.19, pp.2303-2311, 2004. ,
DOI : 10.1093/hmg/ddh238
Epidermal growth factor receptor blockade by antibody IMC-C225 inhibits growth of a human pancreatic carcinoma xenograft in nude mice, Cancer, vol.151, issue.1, pp.74-82, 2000. ,
DOI : 10.1002/1097-0142(20000701)89:1<74::AID-CNCR11>3.0.CO;2-K
EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy, Science, vol.304, issue.5676, pp.1497-1500, 2004. ,
DOI : 10.1126/science.1099314
Rapid Polymerase Chain Reaction-Based Detection of Epidermal Growth Factor Receptor Gene Mutations in Lung Adenocarcinomas, The Journal of Molecular Diagnostics, vol.7, issue.3, pp.396-403, 2005. ,
DOI : 10.1016/S1525-1578(10)60569-7
EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib, Proceedings of the National Academy of Sciences, vol.101, issue.36, pp.13306-13311, 2004. ,
DOI : 10.1073/pnas.0405220101
Epidermal Growth Factor Receptor Mutations, Small-Molecule Kinase Inhibitors, and Non???Small-Cell Lung Cancer: Current Knowledge and Future Directions, Journal of Clinical Oncology, vol.23, issue.11, pp.2556-2568, 2005. ,
DOI : 10.1200/JCO.2005.07.799
Acquired Resistance of Lung Adenocarcinomas to Gefitinib or Erlotinib Is Associated with a Second Mutation in the EGFR Kinase Domain, PLoS Medicine, vol.9, issue.3, p.73, 2005. ,
DOI : 10.1371/journal.pmed.0020073.sd001
KRAS Mutations and Primary Resistance of Lung Adenocarcinomas to Gefitinib or Erlotinib, PLoS Medicine, vol.104, issue.1, p.17, 2005. ,
DOI : 10.1371/journal.pmed.0020017.sd003
Epidermal Growth Factor Receptor Mutations, Small-Molecule Kinase Inhibitors, and Non???Small-Cell Lung Cancer: Current Knowledge and Future Directions, Journal of Clinical Oncology, vol.23, issue.11, pp.2556-2568, 2005. ,
DOI : 10.1200/JCO.2005.07.799
Epidermal Growth Factor Receptor Mutation Testing in Lung Cancer: Searching for the Ideal Method, Clinical Cancer Research, vol.13, issue.17, pp.4954-4955, 2007. ,
DOI : 10.1158/1078-0432.CCR-07-1387
Determinants of Tumor Response and Survival With Erlotinib in Patients With Non???Small-Cell Lung Cancer, Journal of Clinical Oncology, vol.22, issue.16, pp.3238-3247, 2004. ,
DOI : 10.1200/JCO.2004.11.057
Smoking, smoking cessation, and lung cancer in the UK since 1950: combination of national statistics with two case-control studies, BMJ, vol.321, issue.7257, pp.323-329, 2000. ,
DOI : 10.1136/bmj.321.7257.323
K-ras mutation detection in colorectal cancer using the Pyrosequencing technique, Pathology - Research and Practice, vol.203, issue.7, pp.489-497, 2007. ,
DOI : 10.1016/j.prp.2007.06.001
Opinion: Tumour-educated macrophages promote tumour progression and metastasis, Nature Reviews Cancer, vol.4, issue.1, pp.71-78, 2004. ,
DOI : 10.1038/nrc1256
The epidermal growth factor receptor family as a central element for cellular signal transduction and diversification, Endocrine Related Cancer, vol.8, issue.1, pp.11-31, 2001. ,
DOI : 10.1677/erc.0.0080011
Enhanced antitumor activity of anti-epidermal growth factor receptor monoclonal antibody IMC-C225 in combination with irinotecan (CPT-11) against human colorectal tumor xenografts, Clin Cancer Res, vol.8, pp.994-1003, 2002. ,
Cancer incidence and mortality in France over the period, Rev Epidemiol Sante Publique, vol.51, pp.3-30, 1978. ,
URL : https://hal.archives-ouvertes.fr/hal-00428273
PCR-introduced loop structure as primer in DNA sequencing, Biotechniques, vol.25, pp.876-878, 1998. ,
DNA SEQUENCING:A Sequencing Method Based on Real-Time Pyrophosphate, Science, vol.281, issue.5375, pp.363-365, 1998. ,
DOI : 10.1126/science.281.5375.363
Randomized phase II study of cetuximab plus cisplatin/vinorelbine compared with cisplatin/vinorelbine alone as first-line therapy in EGFR-expressing advanced non-small-cell lung cancer, Annals of Oncology, vol.19, issue.2, pp.362-369, 2008. ,
DOI : 10.1093/annonc/mdm474
Epidermal growth factor-related peptides and their receptors in human malignancies, Critical Reviews in Oncology/Hematology, vol.19, issue.3, pp.183-232, 1995. ,
DOI : 10.1016/1040-8428(94)00144-I
Phase II Trial of Cetuximab in Patients With Refractory Colorectal Cancer That Expresses the Epidermal Growth Factor Receptor, Journal of Clinical Oncology, vol.22, issue.7, pp.1201-1208, 2004. ,
DOI : 10.1200/JCO.2004.10.182
Randomized phase II trial of cetuximab/bevacizumab/irinotecan (CBI) versus cetuximab/bevacizumab (CB) in irinotecan-refractory colorectal cancer, Journal of Clinical Oncology, vol.23, issue.16_suppl, pp.3508-1205, 2005. ,
DOI : 10.1200/jco.2005.23.16_suppl.3508
Cancer survival increases in Europe, but international differences remain wide, European Journal of Cancer, vol.37, issue.13, pp.1659-1667, 2001. ,
DOI : 10.1016/S0959-8049(01)00206-4
Biological effects in vitro of monoclonal antibodies to human epidermal growth factor receptors, Mol Biol Med, vol.1, pp.511-529, 1983. ,
Comparison of Four Chemotherapy Regimens for Advanced Non???Small-Cell Lung Cancer, New England Journal of Medicine, vol.346, issue.2, pp.92-98, 2002. ,
DOI : 10.1056/NEJMoa011954
Monoclonal antibodies against receptor for epidermal growth factor induce early and delayed effects of epidermal growth factor., Proceedings of the National Academy of Sciences, vol.78, issue.12, pp.7535-7539, 1981. ,
DOI : 10.1073/pnas.78.12.7535
Molecular Predictors of Response to Epidermal Growth Factor Receptor Antagonists in Non???Small-Cell Lung Cancer, Journal of Clinical Oncology, vol.25, issue.5, pp.587-595, 2007. ,
DOI : 10.1200/JCO.2006.07.3585
Practical Management of Patients With Non???Small-Cell Lung Cancer Treated With Gefitinib, Journal of Clinical Oncology, vol.23, issue.1, pp.165-174, 2005. ,
DOI : 10.1200/JCO.2005.04.057
Epidermal growth factor receptor mutations in lung cancer, Nature Reviews Cancer, vol.64, issue.3, pp.169-181, 2007. ,
DOI : 10.1038/nrc2088
Erlotinib in Previously Treated Non???Small-Cell Lung Cancer, New England Journal of Medicine, vol.353, issue.2, pp.123-132, 2005. ,
DOI : 10.1056/NEJMoa050753
Surgical therapy for carcinoma of the lung, Clin Chest Med, vol.14, pp.121-147, 1993. ,
Clinical and Biological Features Associated With Epidermal Growth Factor Receptor Gene Mutations in Lung Cancers, JNCI Journal of the National Cancer Institute, vol.97, issue.5, pp.339-346, 2005. ,
DOI : 10.1093/jnci/dji055
Strain-dependent epithelial defects in mice lacking the EGF receptor, Science, vol.269, issue.5221, pp.234-238, 1995. ,
DOI : 10.1126/science.7618085
Mutations in the epidermal growth factor receptor gene are linked to smoking-independent, lung adenocarcinoma, British Journal of Cancer, vol.2, issue.3, pp.355-363, 2005. ,
DOI : 10.1038/sj.bjc.6602707
Mutational analysis of EGFR and K-RAS genes in lung adenocarcinomas, Virchows Archiv, vol.62, issue.5, pp.483-488, 2005. ,
DOI : 10.1007/s00428-005-1254-y
Lung Cancer???Where Are We Today?, American Journal of Respiratory and Critical Care Medicine, vol.166, issue.9, pp.1166-1196, 2002. ,
DOI : 10.1164/rccm.200202-070SO
Effect of Fixatives and Tissue Processing on the Content and Integrity of Nucleic Acids, The American Journal of Pathology, vol.161, issue.6, pp.1961-1971, 2002. ,
DOI : 10.1016/S0002-9440(10)64472-0
The E5 oncoprotein of human papillomavirus type 16 inhibits the acidification of endosomes in human keratinocytes, J Virol, vol.69, pp.3185-3192, 1995. ,
Mutation profile of EGFR gene detected by denaturing high-performance liquid chromatography in Japanese lung cancer patients, Journal of Cancer Research and Clinical Oncology, vol.29, issue.2, pp.93-102, 2007. ,
DOI : 10.1007/s00432-006-0144-2
Mutations within the tyrosine kinase domain of EGFR gene specifically occur in lung adenocarcinoma patients with a low exposure of tobacco smoking, British Journal of Cancer, vol.11, issue.6, pp.896-903, 2006. ,
DOI : 10.1016/j.lungcan.2005.08.006
Phase II Trial of Cetuximab in Combination With Fluorouracil, Leucovorin, and Oxaliplatin in the First-Line Treatment of Metastatic Colorectal Cancer, Journal of Clinical Oncology, vol.25, issue.33, pp.5225-5232, 2007. ,
DOI : 10.1200/JCO.2007.13.2183
Epidermal Growth Factor Receptor Gene Mutations and Increased Copy Numbers Predict Gefitinib Sensitivity in Patients With Recurrent Non???Small-Cell Lung Cancer, Journal of Clinical Oncology, vol.23, issue.28, pp.6829-6837, 2005. ,
DOI : 10.1200/JCO.2005.01.0793
Detection of BRAF V600E mutation by pyrosequencing, Pathology, vol.40, issue.3, pp.295-298, 2008. ,
DOI : 10.1080/00313020801911512
Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer), The Lancet, vol.366, issue.9496, pp.1527-1537, 2005. ,
DOI : 10.1016/S0140-6736(05)67625-8
Sensitive mutation detection in heterogeneous cancer specimens by massively parallel picoliter reactor sequencing, Rothberg JM, Meyerson M Nat Med, vol.12, pp.852-855, 2006. ,
Targeted disruption of mouse EGF receptor: effect of genetic background on mutant phenotype of erlotinib versus placebo in the treatment of non-small cell lung cancer, Science J Clin Oncol, vol.269, issue.24, pp.230-234, 1995. ,
An analysis of the prognostic and predictive importance of K-ras mutation status in the National Cancer Institute of Canada Clinical Trials Group BR.21 stud ASSTRACT 8 aogro un<1 : Eplclonnlll Otowfl FK1at. lyrt>IOne IGnoH 1n1>1Mc:n (EGFR.fl(l1f, l>y. Alflo.q. , n no1 0, 2006. ,
prl<liclf,oool.incxyolEOFR-TKl .. ll.y.,en01uMC1.,dnlUlpnH:llCO. n ... a. 1ori, pp.1-1 ,
P?"i:>l0gl011 p.,t1 ,. H torm.:1 . -"'t>otomt1tOC>J-.bUl"ol'lr'Olwulo..,...uoto"oOl>lllyoleocnc.,!?lopolformO!Omlll<« uuyonpwll!lwl, Ot001 .... lt<l!n>mn0t1·tnlOl<nl NSIWWlltn101n(F)Wlt\O ,
ONA?"1r-.c?1ol, tcm 7 ? ..,n;JIUlly!HOC1it<INSCLCofwhJçn ,
0'1'1toNSAI 1'llln'IOcllnell>OlfK1a oeoi:Ror><1~, 1lnelll>Ot.,0<1"0M1'?cap.oty !Og .... COt1Wd..,l!~ l l ,